Ironwood Pharmaceuticals, Inc. - Class A (IRWD) Stock Price

IRWDStock

$3.50+125.81%52W

Market Cap$578.34M

P/E24.08x

PEG Ratio—

Div yield—

Beta0.23

IRWD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-23.27%

Price vs S&P 500 (4W)-19.31%

VGM Score68.53

P/E Ratio (Annual)24.08x

P/CF (Annual)4.55x

Book Value / Share (Quarterly)$4.55

P/TBV (Annual)2.30x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-10.32%

Cash Flow / Share (Quarterly)$1.12

Price vs S&P 500 (YTD)-8.07%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)33.36%

EPS (TTM)$0.76

10-Day Avg Trading Volume1.92M

EPS Excl Extra (TTM)$0.76

Revenue Growth (5Y)-5.33%

EPS (Annual)$0.15

ROI (Annual)16.69%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-9.53%

Cash / Share (Quarterly)$0.48

P/E Basic Excl Extra (TTM)4.45x

Revenue Growth QoQ (YoY)32.62%

EPS Growth (5Y)-25.92%

P/E Normalized (Annual)24.08x

ROA (Last FY)6.05%

Revenue Growth TTM (YoY)26.19%

EBITD / Share (TTM)$1.49

ROE (5Y Avg)-206.33%

Operating Margin (TTM)60.15%

Cash Flow / Share (Annual)$0.78

P/B Ratio0.82x

P/B Ratio (Quarterly)2.31x

Net Income / Employee (Annual)$240,200

EV / Revenue (TTM)2.27x

Net Interest Coverage (TTM)3.44x

ROA (TTM)34.34%

EPS Growth QoQ (YoY)129.81%

EV / EBITDA (TTM)3.75x

EPS Incl Extra (Annual)$0.15

Current Ratio (Annual)1.13x

Quick Ratio (Quarterly)5.84x

3-Month Avg Trading Volume2.18M

52-Week Price Return125.81%

EV / Free Cash Flow (Annual)6.96x

P/E Incl Extra (TTM)4.45x

Revenue / Employee (TTM)$3,893,200

Tangible BV / Share (Quarterly)$-2.10

P/S Ratio (Annual)1.95x

Asset Turnover (Annual)0.75x

52-Week High$5.78

Operating Margin (5Y Avg)-7.34%

EPS Excl Extra (Annual)$0.15

CapEx CAGR (5Y)-54.79%

26-Week Price Return-13.37%

Quick Ratio (Annual)1.08x

13-Week Price Return-9.33%

Total Debt / Equity (Annual)0.61x

Current Ratio (Quarterly)6.06x

Enterprise Value$884.21M

Revenue / Share Growth (5Y)-5.60%

Asset Turnover (TTM)1.03x

Book Value / Share Growth (5Y)44.86%

Revenue / Employee (Annual)$2,961,500

Inventory Turnover (Annual)79.67x

Pretax Margin (Annual)23.65%

Cash / Share (Annual)$1.32

3-Month Return Std Dev59.45%

Gross Margin (5Y Avg)96.84%

Net Income / Employee (TTM)$1,298,700

EBITDA CAGR (5Y)-7.28%

EBITDA Interim CAGR (5Y)4.02%

ROE (Last FY)26.83%

Net Interest Coverage (Annual)8.68x

EPS Basic Excl Extra (Annual)$0.15

P/FCF (TTM)3.12x

Receivables Turnover (TTM)3.91x

EV / Free Cash Flow (TTM)4.77x

Total Debt / Equity (Quarterly)0.56x

EPS Incl Extra (TTM)$0.76

Receivables Turnover (Annual)4.60x

ROI (TTM)17.90%

P/S Ratio (TTM)1.49x

Pretax Margin (5Y Avg)-12.39%

Revenue / Share (Annual)$1.82

Tangible BV / Share (Annual)$4.24

Forward P/E3.52x

Free OCF CAGR (5Y)-5.33%

Price vs S&P 500 (52W)110.27%

P/E Ratio (TTM)4.45x

EPS Growth TTM (YoY)2150.00%

Year-to-Date Return3.86%

5-Day Price Return-6.91%

EPS Normalized (Annual)$0.15

ROA (5Y Avg)-28.73%

Net Profit Margin (Annual)8.11%

Month-to-Date Return-11.84%

Cash Flow / Share (TTM)$-5.48

EBITD / Share (Annual)$0.62

EPS Growth (3Y)-46.07%

Operating Margin (Annual)33.26%

LT Debt / Equity (Annual)0.61x

P/CF (TTM)3.12x

ROI (5Y Avg)8.20%

P/E Excl Extra (TTM)4.45x

LT Debt / Equity (Quarterly)0.56x

EPS Basic Excl Extra (TTM)$0.76

P/B Ratio (Annual)2.91x

Inventory Turnover (TTM)16.12x

Pretax Margin (TTM)53.27%

Book Value / Share (Annual)$4.24

Price vs S&P 500 (13W)-12.01%

Net Margin Growth (5Y)-21.54%

Beta0.23x

P/FCF (Annual)4.55x

Revenue / Share (TTM)$2.33

ROE (TTM)29.31%

52-Week Low$1.43

vGradeA

gGradeC

mGradeB

vgmGradeB

IRWD Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	$0.28	$0.31	+12.73%(+$0.03)
Q1 2026	May 7, 2026	$0.24	$0.24	+0.00%(+$0.00)
Q4 2025	Feb 25, 2026	$0.01	-$0.01	-200.00%(-$0.02)
Q3 2025	Nov 10, 2025	$0.12	$0.24	+108.70%(+$0.12)
Q2 2025	Aug 7, 2025	$0.04	$0.14	+250.00%(+$0.10)

IRWD Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.90

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IRWDIronwood Pharmaceuticals, Inc. - Class A	A	C	B	1.5x	26.2%	100.0%	-25.9%	$3.50
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Ironwood Pharmaceuticals, Inc. - Class A

Ironwood Pharmaceuticals is a biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases. The company markets LINZESS and CONSTELLA (both linaclotide) for the treatment of irritable bowel syndrome with constipation, chronic constipation, and functional constipation across North America, Europe, and Asia-Pacific regions.